The target group for boost application turned out to be patients </=50 years and >50 years with established risk factors for recurrences (e.g., triple negative breast carcinoma, G3, Her2-positive, >T1) since, in younger patients, a higher recurrence rate has been recognized [1,27]. The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.